Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Recurrence 1Multiple Myeloma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 10fludarabine 7pomalidomide 5pembrolizumab 5Dexamethasone 5daratumumab 4obinutuzumab 3glofitamab 3fludarabine phosphate 3abemaciclib 3Rituximab 3Melphalan 3Immunotherapy, Adoptive 3Etoposide 3Bortezomib 3zanubrutinib 2venetoclax 2tocilizumab 2pirtobrutinib 2palbociclib 2cemiplimab 2blinatumomab 2Temozolomide 2Sirolimus 2Oxaliplatin 2Nivolumab 2Mesna 2Letrozole 2Injections 2Gemcitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Fumigant 93 × 30 days × Clear all
NCT07623798 2026-06-03

A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3 Not yet recruiting
255 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡